Term
| Disease caused by excess ergot alkaloids |
|
Definition
|
|
Term
| Endogenous substances commonly interpreted as histamine, serotonin, prostaglandins, and vasoactive peptides |
|
Definition
|
|
Term
| Syndrome of hypersecretion of gastric acid and pepsin usually caused by gastrinoma; it is associated with severe peptic ucleration and diarrhea |
|
Definition
| Zollinger-Ellison Syndrome |
|
|
Term
| Drug that causes contraction of the uterus |
|
Definition
|
|
Term
| Distribution of histamine receptors H1, H2, and H3 |
|
Definition
| Smooth muscle; stomach, heart and mast cells; nerve endings, CNS respectively |
|
|
Term
| Prototype antagonist of H1 and H2 receptors |
|
Definition
| Diphenhydramine and ranitidine, respectively |
|
|
Term
| 1st generation antihistamine that is highly sedating |
|
Definition
|
|
Term
| 1st generation antihistamine that is least sedating |
|
Definition
| Chlorpheniramine or cyclizine |
|
|
Term
| 2nd generation antihistamines |
|
Definition
| Fexofenadine (Allegra), loratadine (Claritin), and cetirizine (Zyrtec) |
|
|
Term
| Generation of antihistamine that has the most CNS effects |
|
Definition
| First generation due to being more lipid-soluble |
|
|
Term
| Major indication for H1 receptor antagonist |
|
Definition
| Use in IgE mediated allergic reaction |
|
|
Term
| Antihistamine that can be used for anxiety and insomnia and is not addictive |
|
Definition
|
|
Term
| H1 antagonist used in motion sickness |
|
Definition
| Dimenhydrinate, meclizine, and other 1st generation |
|
|
Term
| Most common SE of 1st generation antihistamines |
|
Definition
|
|
Term
| Lethal arrhythmias resulting from concurrent therapy with azole fungals (metabolized by CYP3A4) and there antihistamines which inhibit the 3A4 iso-enzyme |
|
Definition
| Terfenadine and astemizole (have been removed from market) |
|
|
Term
| H2 blocker that causes the most interactions with other drugs |
|
Definition
|
|
Term
| Clinical use for H2 blockers |
|
Definition
| Acid reflux disorder, duodenal ucler and petic ulcer disease |
|
|
Term
| Receptors for serotonin (5HT-1) are located |
|
Definition
| Mostly in the brain, and they mediate synaptic inhibition via increased K+ conductance |
|
|
Term
| 5HT-1d agonist used for migraine headaches |
|
Definition
| Sumatriptan, naratriptan, and rizatriptan |
|
|
Term
| Triptan available in parenteral and nasal formulations |
|
Definition
|
|
Term
| H1 blocker that is also a serotonin antagonist |
|
Definition
|
|
Term
| Agents for reduction of postpartum bleeding |
|
Definition
| Oxytocin, ergonovine and ergotamine |
|
|
Term
Agents used in treatment of carcinoid tumor |
|
Definition
| Ketanserin, cyproheptadine, and phenoxybenzamine |
|
|
Term
| 5HT-3 antagonist used in chemoterapeutic induced emesis |
|
Definition
| Ondansetron, granisetron, dolasetron, and alosetron |
|
|
Term
| 5HT-3 antagonist that has been associated with QRS and QTc prolongation and should not be used in patients with heart disease |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Drug used in ergot alkaloids overdose, ischemia and gangrene |
|
Definition
|
|
Term
| Reason ergot alkaloids are contraindicated in pregnancy |
|
Definition
|
|
Term
|
Definition
| Hallucinations resembling psychosis |
|
|
Term
| Ergot alkaloid used as an illicit drug |
|
Definition
|
|
Term
| Dopamine agonist used in hyperprolactinemia |
|
Definition
Bromocriptine (Cabergoline, pergolide) |
|
|
Term
| Peptide causing increased capillary permeability and edema |
|
Definition
|
|
Term
| Mediator of tissue pain, edema, inactivated by ACE, and may be a contributing factor to the development of angioedema |
|
Definition
|
|
Term
| 5-HT-1a agonist that is an anxiolytic |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Ergot alkaloid used for migraines |
|
Definition
Ergotamine (partial alpha agonist) |
|
|
Term
| Ergot alkaloid that stimulates uterine SMC contraction; used for postpartum hemorrhage |
|
Definition
|
|
